Terapie imunitní trombocytopenické purpury ve světle nejnovějších doporučení

Číslo: 2 / 2010 (Obsah)
Rubrika: Doporučené postupy
Obor: Hematologie
Autoři: MUDr. Libor Červinek
prof. MUDr. Jiří Mayer, CSc.
Autoři - působiště: Interní hematoonkologická klinika LF MU a FN, Brno
Citace: 1. Rodeghiero F, Stasi R. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–93. 2. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica 2008;93:98–103. 3. Kaznelson P. Verschwinden der Hamorrhagischen Diatese bei einem Falle von essentiele Trombopenie nach Miltz extirpation. Wiener Klinische Wochenschrift 1916;29:1451–4. 4. McMillan R. Therapy for adults with refractory chronic immune trombocytopenic purpura. Ann Intern Med 1997;126:307–14. 5. Douglas BC, Bussel JB. How I treat idiopathic thrombocytopenic purpura. Blood 2005;106:2244–51. 6. Donald MA, Kelton JG. Current options for the treatment of idiopathic trombocytopenic purpura. Semin Hematol 2007; 44(Suppl 5):S12–23 7. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods of American Society of Hematology. Blood 1996;88:3–40. 8. British Committee for Standard in Haematology General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol 2003;120:574–96. 9. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86. 10. Portielje J, Westendorp R, Klui-Nelemans H, et al. Morbility and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54. 11. Beck CE, Nathan PC, Parkin PC. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and metaanalysis of randomized controlled trials. J Pediatr 2005;147:521–7. 12. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82: 1415–21. 13. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985;2:464–8. 14. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune trombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689–700. 15. Zoghlami-Rintelen C, Weltrmann A, Bittermann C, et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol 2003;82:290–4. 16. Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121–5. 17. Reiner A, Gernsheimer T, Schlichter SJ. Pulse cyclofosfamide therapy for refractory aumoimmune thrombocytopenic purpura. Blood 1995;85:351–8. 18. Maloisel F, Andres E, Zimmer J. Danazol therapy in patiens with chronic idiopathic thrombocytopenic purpura. Am J Med 2004;116:590–4. 19. Howard J, Hoffbrand AV, Prentice HG. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anemia and autoimmune thrombocytopenic purpura. Br J Haematol 2002;117:712–5. 20. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopahic thrombocytopenic purpura. Am J Hematol 2005;78:275–80. 21. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149–69. 22. Arnold DA, Dentali F, Crowther MA, et al. Efficacy and safety of rituximab for adults with idiopathic trombocytopenic purpura. Ann Intern Med 2007;146:25–33. 23. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47. 24. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immunethrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395–403. 25. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in helthy mothers and their infants. N Engl J Med 1988; 319:142–5. 26. Letsky EA, Greaves M, et al. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. Br J Haematol 1996;95:21–6.

Souhrn

Imunitní trombocytopenická purpura (ITP), nově též imunitní trombocytopenie, je řazena mezi autoimunitní onemocnění.

Literatura

1. Rodeghiero F, Stasi R. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–93. 2. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica 2008;93:98–103. 3. Kaznelson P. Verschwinden der Hamorrhagischen Diatese bei einem Falle von essentiele Trombopenie nach Miltz extirpation. Wiener Klinische Wochenschrift 1916;29:1451–4. 4. McMillan R. Therapy for adults with refractory chronic immune trombocytopenic purpura. Ann Intern Med 1997;126:307–14. 5. Douglas BC, Bussel JB. How I treat idiopathic thrombocytopenic purpura. Blood 2005;106:2244–51. 6. Donald MA, Kelton JG. Current options for the treatment of idiopathic trombocytopenic purpura. Semin Hematol 2007; 44(Suppl 5):S12–23 7. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods of American Society of Hematology. Blood 1996;88:3–40. 8. British Committee for Standard in Haematology General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol 2003;120:574–96. 9. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86. 10. Portielje J, Westendorp R, Klui-Nelemans H, et al. Morbility and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54. 11. Beck CE, Nathan PC, Parkin PC. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and metaanalysis of randomized controlled trials. J Pediatr 2005;147:521–7. 12. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82: 1415–21. 13. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985;2:464–8. 14. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune trombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689–700. 15. Zoghlami-Rintelen C, Weltrmann A, Bittermann C, et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol 2003;82:290–4. 16. Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121–5. 17. Reiner A, Gernsheimer T, Schlichter SJ. Pulse cyclofosfamide therapy for refractory aumoimmune thrombocytopenic purpura. Blood 1995;85:351–8. 18. Maloisel F, Andres E, Zimmer J. Danazol therapy in patiens with chronic idiopathic thrombocytopenic purpura. Am J Med 2004;116:590–4. 19. Howard J, Hoffbrand AV, Prentice HG. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anemia and autoimmune thrombocytopenic purpura. Br J Haematol 2002;117:712–5. 20. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopahic thrombocytopenic purpura. Am J Hematol 2005;78:275–80. 21. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149–69. 22. Arnold DA, Dentali F, Crowther MA, et al. Efficacy and safety of rituximab for adults with idiopathic trombocytopenic purpura. Ann Intern Med 2007;146:25–33. 23. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47. 24. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immunethrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395–403. 25. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in helthy mothers and their infants. N Engl J Med 1988; 319:142–5. 26. Letsky EA, Greaves M, et al. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. Br J Haematol 1996;95:21–6.

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky